Mankind Pharma Company Research Report

Company Overview

Basic Information

• Name: Mankind Pharma

• Mission: Providing high-quality products at affordable prices with a focus on quality, affordability, and accessibility.

• Founded: 1991

• Commenced Operations: 1995

• Founder(s): No information is available on specific founders.

Key People

• Shri. Ramesh Juneja - Chairman and Whole-Time Director

• Mr. Rajeev Juneja - Managing Director & Vice Chairman

• Mr. Sheetal Arora - Chief Executive Officer and Whole-time Director

• Mr. Arjun Juneja - Chief Operating Officer

Headquarters and Structure

• Headquarters: No specific location mentioned for headquarters.

• Number of Employees: Over 23,000

• Revenue: INR 10,335 Crores for FY 2024

• Market Position: Ranked as India’s fourth-largest pharmaceutical company by domestic sales.

Known For

Mankind Pharma is known for developing, manufacturing, and marketing a broad range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

Products

Product Offering

• Pharmaceutical Formulations:

• Acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins, minerals, and respiratory.

• Consumer Healthcare Products:

• Brands in condoms, pregnancy detection, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations.

Key Product Features

• Domestic Pharmaceuticals: Comprehensive portfolio with focus on quality and affordability.

• Consumer Healthcare: Differentiated brands catering to various consumer needs.

Recent Developments

Recent Major Developments

• 2024: In-licensed Symbicort from AstraZeneca.

• 2023:

• Listed on NSE and BSE.

• Launched international quality API products.

• Established an integrated facility for Dydrogesterone in Udaipur.

• 2022:

• Acquired pharmaceutical formulation brands in India and Nepal from Panacea Biotec Pharma Limited.

• Expanded into transplant and oncology segments with new product launches.

• 2021: Entered specialty therapeutic segments like respiratory and neuro/CNS.

New Products and Partnerships

• New Products:

• ‘Pangraf Capsules’ and ‘Mycept’ tablets for transplant.

• Oncology drug ‘Pacliall Injection.’

• Partnerships/Acquisitions: Acquired brands from Dr. Reddy’s Laboratories and Panacea Biotec.

Research and Development

• R&D Infrastructure: Dedicated research centers located in Gurugram, Haryana, and Thane, Maharashtra. Subsidiaries operate additional centers in Dehradun and Paonta Sahib.

• R&D Achievements: Submitted 60 ANDAs with USFDA, 41 approvals with additional ROW drug product applications.

Awards & Recognition

• 2024: International Safety Award from British Safety Council; Multiple awards at NCQC-2024 and for manufacturing excellence.

• 2023: Received The Economic Times Award 2023 Entrepreneur of the Year and other accolades for innovation and industry leadership.

Financial Overview

• Quarterly Reports: Regular intimation to stock exchanges under SEBI norms—latest results and announcements for quarterly performance and acquisitions.

• Acquisitions: Recently announced acquisition of Bharat Serums and Vaccines Limited with an aim to expand product portfolio and market reach.

Contact Information

• Website: Visit [Mankind Pharma](#) for further details and direct inquiries.

Conclusion

Mankind Pharma stands as a significant player in India's pharmaceutical sector, deeply embedded in both therapeutic and consumer healthcare domains. The company’s strong commitment to quality, affordability, and accessibility underscores its market strategies and product offerings.